XML 35 R25.htm IDEA: XBRL DOCUMENT v3.21.1
Revenue (Tables)
3 Months Ended
Mar. 31, 2021
Revenue from Contract with Customer [Abstract]  
Schedule of Total Revenue by Product and by U.S versus Rest of World
The following table presents detail regarding the composition of the Company’s total revenue by product and by U.S. versus rest of world (“RoW”):
Three Months Ended March 31,
20212020
(in millions)U.S.RoWTotalU.S.RoWTotal
Molecular diagnostic revenues:
Hereditary Cancer Testing$65.1 $11.0 $76.1 $81.3 $3.9 $85.2 
Prenatal23.6 0.1 23.7 20.2 0.1 20.3 
GeneSight17.6 — 17.6 20.4 — 20.4 
Vectra10.7 — 10.7 10.5 — 10.5 
myChoice CDx4.8 3.6 8.4 3.2 0.1 3.3 
Prolaris18.5 — 18.5 6.8 — 6.8 
EndoPredict0.9 3.2 4.1 0.6 2.9 3.5 
Other— 0.5 0.5 0.4 0.1 0.5 
Total molecular diagnostic revenue141.2 18.4 159.6 143.4 7.1 150.5 
Pharmaceutical and clinical service revenue13.5 — 13.5 9.6 3.9 13.5 
Total revenue$154.7 $18.4 $173.1 $153.0 $11.0 $164.0 
Reconciliation of Deferred Revenue Balances A reconciliation of the beginning and ending balances of deferred revenue is shown in the table below:
Three Months Ended
March 31,
(in millions)20212020
Deferred revenue - beginning balance$32.7 $3.6 
Revenue recognized(6.7)(1.3)
Prepayments5.1 1.5 
Deferred revenue - ending balance$31.1 $3.8